Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a…
Read MoreVANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the appointment of Julie M. Eastland to the Board of Directors, effective immediately. Ms. Eastland is a…
Read MoreVANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX-V:PAS) (Pascal), is pleased to announce significant progress in its cannabinoid based research and development program with the University of British Columbia (UBC). Pascal has been licensed by…
Read MoreVANCOUVER, BRITISH COLUMBIA and SEATTLE, WASHINGTON, February 21, 2018 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system.…
Read MoreVANCOUVER, B.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE:PAS), a biotechnology company that specializes in cancer drug discovery and development, today announced the appointment of Dr. Graeme I. Bell to its Board of Directors.…
Read MoreVANCOUVER, BRITISH COLUMBIA, September 11, 2017 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that the Company has executed an exclusive, worldwide license option agreement with STC.UNM (“STC”), the University of New…
Read MoreVANCOUVER, BRITISH COLUMBIA, May 9, 2017 --Pascal Biosciences Inc. (formerly bioMmune Technologies Inc.) (TSX.V/PAS) (“Pascal” or the “Company”), a biotechnology company that specializes in drug discovery and development, is pleased to announce that the Company has created a new, wholly…
Read MoreVANCOUVER, BRITISH COLUMBIA, March 30, 2017 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”), a Vancouver-based biotechnology company, is pleased to announce that effective Thursday, March 30, 2017, the Company has changed its name to Pascal Biosciences Inc. (“Pascal”). Effective…
Read MoreVANCOUVER, BRITISH COLUMBIA, November 14, 2016 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”) announces the approval and adoption by its Board of Directors of an advance notice policy (the "Policy"). The purpose of the Policy is to provide shareholders,…
Read MoreVANCOUVER, BRITISH COLUMBIA, October 5, 2016 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”) is pleased to announce that pursuant to the Company’s Incentive Stock Option Plan (the “Plan”), it has granted incentive stock options to directors and officers of the Company…
Read More